Contribute Try STAT+ Today

Late at night, in a California hospital, a brain-dead patient was being prepared to offer the ultimate gift. That May evening in 2019, she would be taken off her ventilator, and many of her organs and tissues — everything from the bladder to the lungs to muscle — would be donated to a unique project led by the Chan Zuckerberg Biohub.

Many patients and their families choose to support scientific research with their bodies after passing. But this gift in particular would require immense logistical precision. The Biohub project, called Tabula Sapiens, aims to create an atlas of single-cell gene expression that, unlike most existing databases, contains sequences from a single donor’s cells. That approach allows scientists to control for factors like genetic inheritance, age, epigenetics, and environment — but it also means every organ needs to be collected and preserved simultaneously, as soon after death as possible. Wait too long, and the delicate RNA within their cells will begin to degrade, destroying evidence of the work they were doing in the once-living body.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I share an interest in figuring out how much diversity there is in the transcription profiles of single cells. But how will it be linked to the biology?

Comments are closed.